At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
PMN310 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of PMN310 Infusions in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating PMN310 and Placebo for Healthy Participants. Completed, enrolled 40 participants across 2 sites.
Detailed Summary
This first in human Phase 1a clinical trial will evaluate the safety, tolerability, and pharmacokinetics of a single IV infusion of PMN310 in healthy volunteers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedOct 2023
Enrollment StartNov 2023
Primary CompletionJul 2024
TodayJul 2026
First PostedOct 27, 2023
Enrollment StartNov 18, 2023
Primary CompletionJul 31, 2024
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 2.7 years ago
Interventions
PMN310drug
60-minute intravenous infusion
Placebodrug
60-minute intravenous infusion